Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 7Carcinoma, Transitional Cell 7Ureteral Neoplasms 3Urologic Neoplasms 2Neoplasm Metastasis 2Urothelial Cancer 1Urologic Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Urethral Neoplasms 1Peripheral Nervous System Diseases 1Neoplasms by Site 1Neoplasms 1Muscle-invasive Bladder Cancer 1Muscle Invasive Bladder Urothelial Carcinoma 1Male Urogenital Diseases 1Female Urogenital Diseases 1Adenocarcinoma of the Bladder 1

Interventions

pembrolizumab 1enfortumab vedotin 1Fish Oils 1Corn Oil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Peripheral Nervous System Diseases × enfortumab vedotin × 30 days × Clear all
NCT07484022 2026-06-03

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Generate Biomedicines

Phase 1 Recruiting
37 enrolled
Genitourinary

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡